首页> 外文期刊>The British journal of general practice: the journal of the Royal College of General Practitioners >Atrial fibrillation and stroke prevention: where we are and where we should be (vol 68, pg 260, 2018)

【24h】

Atrial fibrillation and stroke prevention: where we are and where we should be (vol 68, pg 260, 2018)

机译：心房颤动和冲程预防：我们在哪里以及我们应该在哪里（Vol 68，PG 260,2018）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The British journal of general practice: the journal of the Royal College of General Practitioners》 |2018年第673期|共1页
作者
Taylor Clare J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. Atrial fibrillation and stroke prevention: where we are and where we should be (vol 68, pg 260, 2018) [J] . Taylor Clare J. The British journal of general practice: the journal of the Royal College of General Practitioners . 2018,第673期

机译：心房颤动和冲程预防：我们在哪里以及我们应该在哪里（Vol 68，PG 260,2018）
2. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (130, pg 138, 2014) [J] . Halperin Jonathan L., Hankey Graeme J., Wojdyla Daniel M., Circulation: An Official Journal of the American Heart Association . 2018,第25期

机译：Rivaroxaban的疗效和安全性与罗西沙巴少年患者的老年患者患者，口服，直接因子XA抑制与维生素K拮抗作用，用于预防心房颤动（Rocket AF）（130，Pg 138,2014）
3. Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Piccini Jonathan P., Stevens Susanna R., Chang YuChiao, Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：对有关“非瓣膜性房颤患者中风和全身性栓塞的预测指标：肾功能不全：ROCKET AF（Rivaroxaban每日一次，口服，直接因素）中的R（2）CHADS（2）指数的验证的答复Xa抑制与维生素K拮抗剂在房颤预防卒中和栓塞试验中的比较以及ATRIA（房颤的抗凝和危险因素）研究队列”
4. Early Experiences from a Guideline-based Computerized Clinical Decision Support for Stroke Prevention in Atrial Fibrillation [C] . Rong Chen, Carlos Vailadares, Iago Corbal, MEDINFO . 2013

机译：基于指南的计算机化临床决策支持的早期经验支持心房颤动中的中风预防
5. Comparative and Cost-effectiveness of Stroke Prevention Treatments in Atrial Fibrillation: A New Generation of Drugs. [D] . Tawfik, Amy. 2015

机译：心房颤动中风预防治疗的比较和成本效益：新一代药物。
6. Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients [O] . B. Bielecka, I. Gorczyca, O. Jelonek, 2021

机译：2014年和2018年在住院心房颤动患者中卒中预防趋势
7. Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts” [O] . Jonathan P. Piccini, Susanna R. Stevens, YuChiao Chang, 2013

机译：回应关于物品的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R 2 Chads 2指数在火箭AF中（rivaroxaban曾经每日，口服，直接因子XA抑制相比维生素K对患者预防心房颤动的卒中和栓塞试验的拮抗剂）和Atria（心房颤动的抗凝和危险因素）研究队列“

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号